Huimin Li1, Jie Lu, Jinrong Liu, Yuhong Zhao, Xin Ni, Shunying Zhao. 1. From the *Beijing Children's Hospital, Capital Medical University, Beijing, China; and †Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing, China.
Abstract
BACKGROUND: Linezolid serves as an important component for the treatment of drug-resistant tuberculosis although there is little published data about linezolid use in children, especially in childhood tuberculous meningitis (TBM). METHODS: In this study, we retrospectively reviewed records of childhood TBM patients who started treatment between January 2012 and August 2014. A total of 86 childhood TBM patients younger than 15 years old were enrolled. Out of 86 children, 36 (41.9%) received the regimen containing linezolid. RESULTS: Thirty-two (88.9%) of 36 linezolid-treated cases had favorable outcomes, and 35 (70.0%) cases were successfully treated in the control group. The frequency of favorable outcome of linezolid group was significantly higher than that of control group (P = 0.037). In addition, compared with cases with fever clearance time of <1 week, the control group had more cases with fever clearance time of 1-4 weeks (P = 0.010) and >4 weeks (P = 0.000) than linezolid group. Furthermore, there was no significant difference in the frequency of adverse events between the two regimens (P = 0.896). In addition, the patients with adverse events were more likely to have treatment failure, the P value of which was 0.008. CONCLUSIONS: Our data demonstrate that linezolid improves early outcome of childhood TBM. The low frequency of linezolid-associated adverse effects highlights the promising prospects of its use for treatment of childhood TBM.
BACKGROUND:Linezolid serves as an important component for the treatment of drug-resistant tuberculosis although there is little published data about linezolid use in children, especially in childhood tuberculous meningitis (TBM). METHODS: In this study, we retrospectively reviewed records of childhood TBM patients who started treatment between January 2012 and August 2014. A total of 86 childhood TBM patients younger than 15 years old were enrolled. Out of 86 children, 36 (41.9%) received the regimen containing linezolid. RESULTS: Thirty-two (88.9%) of 36 linezolid-treated cases had favorable outcomes, and 35 (70.0%) cases were successfully treated in the control group. The frequency of favorable outcome of linezolid group was significantly higher than that of control group (P = 0.037). In addition, compared with cases with fever clearance time of <1 week, the control group had more cases with fever clearance time of 1-4 weeks (P = 0.010) and >4 weeks (P = 0.000) than linezolid group. Furthermore, there was no significant difference in the frequency of adverse events between the two regimens (P = 0.896). In addition, the patients with adverse events were more likely to have treatment failure, the P value of which was 0.008. CONCLUSIONS: Our data demonstrate that linezolid improves early outcome of childhood TBM. The low frequency of linezolid-associated adverse effects highlights the promising prospects of its use for treatment of childhood TBM.
Authors: Angharad G Davis; Sean Wasserman; Mpumi Maxebengula; Cari Stek; Marise Bremer; Remy Daroowala; Saalikha Aziz; Rene Goliath; Stephani Stegmann; Sonya Koekemoer; Amanda Jackson; Louise Lai Sai; Yakub Kadernani; Thandi Sihoyiya; C Jason Liang; Lori Dodd; Paolo Denti; Thomas Crede; Jonathan Naude; Patryk Szymanski; Yakoob Vallie; Ismail Banderker; Shiraz Moosa; Peter Raubenheimer; Rachel P J Lai; John Joska; Sam Nightingale; Anna Dreyer; Gerda Wahl; Curtis Offiah; Isak Vorster; Sally Candy; Frances Robertson; Ernesta Meintjes; Gary Maartens; John Black; Graeme Meintjes; Robert J Wilkinson Journal: Wellcome Open Res Date: 2021-06-01